G2539
Glyburide
meets USP testing specifications
別名:
グリベンクラミド, 5-クロロ-N-[4-(シクロヘキシルウレイドスルホニル)フェネチル]-2-メトキシベンズアミド, N-p-[2-(5-クロロ-2-メトキシベンズアミド)エチル]ベンゼンスルホニル-N′-シクロヘキシル尿素, グリブリド
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C23H28ClN3O5S
CAS番号:
分子量:
494.00
NACRES:
NA.21
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
233-570-6
MDL number:
Quality level:
Quality Level
agency
USP/NF, meets USP testing specifications
application(s)
pharmaceutical (small molecule)
storage temp.
2-8°C
SMILES string
COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI
1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
InChI key
ZNNLBTZKUZBEKO-UHFFFAOYSA-N
Gene Information
human ... ABCC8(6833), KCNH2(3757), KCNJ11(3767)
rat ... Kcnj1(24521)
Still not finding the right product?
Explore all of our products under Glyburide
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 4
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Khac-Minh Thai et al.
Bioorganic & medicinal chemistry, 16(7), 4107-4119 (2008-02-05)
Acquired long QT syndrome causes severe cardiac side effects and represents a major problem in clinical studies of drug candidates. One of the reasons for development of arrhythmias related to long QT is inhibition of the human ether-a-go-go-related-gene (hERG) potassium
Ruchira M Jha et al.
Journal of neurotrauma, 38(5), 628-645 (2020-11-19)
Glibenclamide (GLY) is the sixth drug tested by the Operation Brain Trauma Therapy (OBTT) consortium based on substantial pre-clinical evidence of benefit in traumatic brain injury (TBI). Adult Sprague-Dawley rats underwent fluid percussion injury (FPI; n = 45), controlled cortical impact (CCI;
Kevin N Sheth et al.
Stroke, 45(1), 281-283 (2013-11-07)
Preclinical and retrospective clinical data indicate that glyburide, a selective inhibitor of sulfonylurea receptor 1-transient receptor potential melastatin 4, is effective in preventing edema and improving outcome after focal ischemia. We assessed the feasibility of recruiting and treating patients with